Indeterminate/moderate IgG avidity during HCMV infection: comparison of methods

Main Article Content

Massimo De Paschale *
Alessia Paganini
Maria Teresa Manco
Laura Marinoni
Luigi Bertinotti
Carlo Agrappi
Paola Mirri
Arianna Gatti
Cristina Rescaldani
Pierangelo Clerici
(*) Corresponding Author:
Massimo De Paschale | massimo.depaschale@ao-legnano.it

Abstract

Background. The IgG avidity test is usually used for differentiating between primary and non-primary HCMV infection within 3 months. Weak avidity is highly suggestive of a primary infection, while high avidity tends to exclude it.An indeterminate or moderate avidity, however, does not allow a clear dating. Since there are several avidity tests with different performances, those tests that are able to minimize the results with indeterminate/moderate avidity are particularly useful. Objectives. The aim of our work was to evaluate the results obtained with two IgG avidity tests in IgG and IgM anti-HCMV positive patients. Study Design. 113 anti-HCMV IgG and IgM positive samples were tested with Enzime Linked Fluorescent Assay (ELFA) and Chemiluminescence Immuno Assay (CLIA) IgG avidity test. Results. 21 samples (18.6%), 50 (44.2%) and 42 (37.2%) with ELFA and 53 samples (46.9%), 10 (8.8%) and 50 (44.2%) with CLIA were found to have respectively low, indeterminate/moderate and high avidity. Of the 50 ELFA indeterminate avidity samples, 32 (64%), 10 (20%) and 8 (16%) were found to have respectively low, moderate and high CLIA.avidity. For 11 cases of the 32 ELFA indeterminate avidity and CLIA low avidity, there were previous data showing a seroconversion within three months. In a case of the 8 ELFA indeterminate avidity and CLIA high avidity, there were, instead, previous data of IgG and IgM positivity already four months earlier. Conclusions. It appears that the CLIA test for IgG avidity is more effective than ELFA for dating HCMV infection.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

Most read articles by the same author(s)

1 2 > >>